These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 30136205)

  • 1. Mutation in the VP2 gene of P1-2A capsid protein increases the thermostability of virus-like particles of foot-and-mouth disease virus serotype O.
    Ganji VK; Biswal JK; Lalzampuia H; Basagoudanavar SH; Saravanan P; Tamil Selvan RP; Umapathi V; Reddy GR; Sanyal A; Dechamma HJ
    Appl Microbiol Biotechnol; 2018 Oct; 102(20):8883-8893. PubMed ID: 30136205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Heat-Induced Mutation on VP1 of Foot-and-Mouth Disease Virus Serotype O Enhanced Capsid Stability and Immunogenicity.
    Dong H; Lu Y; Zhang Y; Mu S; Wang N; Du P; Zhi X; Wen X; Wang X; Sun S; Zhang Y; Guo H
    J Virol; 2021 Jul; 95(16):e0017721. PubMed ID: 34011545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric virus-like particles elicit protective immunity against serotype O foot-and-mouth disease virus in guinea pigs.
    Liu X; Fang Y; Zhou P; Lu Y; Zhang Q; Xiao S; Dong Z; Pan L; Lv J; Zhang Z; Zhang Y; Wang Y
    Appl Microbiol Biotechnol; 2017 Jun; 101(12):4905-4914. PubMed ID: 28365796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel expression of immunogenic foot-and-mouth disease virus-like particles in Nicotiana benthamiana.
    Veerapen VP; van Zyl AR; Wigdorovitz A; Rybicki EP; Meyers AE
    Virus Res; 2018 Jan; 244():213-217. PubMed ID: 29196195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and prophylactic potential of a stabilized foot-and-mouth disease serotype Asia1 virus like particles designed through a structure guided approach.
    Aparna M; Saravanan P; Dhanesh VV; Selvaraj DPR; Shreya G; Adwitiya D; Madhusudan H; Sreenivasa BP; Tamilselvan RP; Sanyal A; Goyal S; Thiyagarajan S; Chaudhuri P
    Int J Biol Macromol; 2024 Oct; 277(Pt 4):134366. PubMed ID: 39098702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel chimeric foot-and-mouth disease virus-like particles harboring serotype O VP1 protect guinea pigs against challenge.
    Li H; Li Z; Xie Y; Qin X; Qi X; Sun P; Bai X; Ma Y; Zhang Z
    Vet Microbiol; 2016 Feb; 183():92-6. PubMed ID: 26790940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and protective efficacy of a novel foot-and-mouth disease virus empty-capsid-like particle with improved acid stability.
    Xie Y; Li H; Qi X; Ma Y; Yang B; Zhang S; Chang H; Yin X; Li Z
    Vaccine; 2019 Mar; 37(14):2016-2025. PubMed ID: 30808570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric Porcine Parvovirus VP2 Virus-like Particles with Epitopes of South African Serotype 2 Foot-and-Mouth Disease Virus Elicits Specific Humoral and Cellular Responses in Mice.
    Li Q; Ma X; Shen Y; Dai J; Nian X; Shang X; Chen J; Wubshet AK; Zhang J; Zheng H
    Viruses; 2024 Apr; 16(4):. PubMed ID: 38675963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of acid resistant virus like particles of vaccine strains of foot-and-mouth disease virus (FMDV).
    Deepak PR; Saravanan P; Biswal JK; Basagoudanavar SH; Dechamma HJ; Umapathi V; Sreenivasa BP; Tamilselvan RP; Krishnaswamy N; Zaffer I; Sanyal A
    Biologicals; 2019 Jul; 60():28-35. PubMed ID: 31221554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel immunogenic baculovirus expressed virus-like particles of foot-and-mouth disease (FMD) virus protect guinea pigs against challenge.
    Bhat SA; Saravanan P; Hosamani M; Basagoudanavar SH; Sreenivasa BP; Tamilselvan RP; Venkataramanan R
    Res Vet Sci; 2013 Dec; 95(3):1217-23. PubMed ID: 23969204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of virus like particle (VLP) vaccine of foot-and-mouth-disease virus (FMDV) type O adjuvanted with poly I:C or CpG in guinea pigs.
    Terhuja M; Saravanan P; Tamilselvan RP
    Biologicals; 2015 Nov; 43(6):437-43. PubMed ID: 26493006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoreactivity and trypsin sensitivity of recombinant virus-like particles of foot-and-mouth disease virus.
    Basagoudanavar SH; Hosamani M; Tamil RP; Sreenivasa BP; Chandrasekhar BK; Venkataramanan R
    Acta Virol; 2015 Mar; 59(1):84-91. PubMed ID: 25790055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent neutralization activity against type O foot-and-mouth disease virus elicited by a conserved type O neutralizing epitope displayed on bovine parvovirus virus-like particles.
    Chang J; Zhang Y; Yang D; Jiang Z; Wang F; Yu L
    J Gen Virol; 2019 Feb; 100(2):187-198. PubMed ID: 30547855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and antigenic relationship of foot-and-mouth disease virus serotype O isolates with the vaccine strain O1/BFS.
    Xu W; Zhang Z; Nfon C; Yang M
    Vaccine; 2018 Jun; 36(26):3802-3808. PubMed ID: 29776753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promising MS2 mediated virus-like particle vaccine against foot-and-mouth disease.
    Dong YM; Zhang GG; Huang XJ; Chen L; Chen HT
    Antiviral Res; 2015 May; 117():39-43. PubMed ID: 25676866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prime-Boost Vaccination Strategy in Cattle to Prevent Foot-and-Mouth Disease Using a "Single-Cycle" Alphavirus Vector and Empty Capsid Particles.
    Gullberg M; Lohse L; Bøtner A; McInerney GM; Burman A; Jackson T; Polacek C; Belsham GJ
    PLoS One; 2016; 11(6):e0157435. PubMed ID: 27294397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of the thermofluor PaSTRy technique for improving foot-and-mouth disease virus vaccine formulation.
    Kotecha A; Zhang F; Juleff N; Jackson T; Perez E; Stuart D; Fry E; Charleston B; Seago J
    J Gen Virol; 2016 Jul; 97(7):1557-1565. PubMed ID: 27002540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of foot-and-mouth disease virus (FMDV) serotype O virus-like-particles (VLPs) vaccine and evaluation of its potency.
    Mohana Subramanian B; Madhanmohan M; Sriraman R; Chandrasekhar Reddy RV; Yuvaraj S; Manikumar K; Rajalakshmi S; Nagendrakumar SB; Rana SK; Srinivasan VA
    Antiviral Res; 2012 Dec; 96(3):288-95. PubMed ID: 23043941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced protective immune response of foot-and-mouth disease vaccine through DNA-loaded virus-like particles.
    Lu Y; Dong H; Li J; Li L; Wang M; Liu H; Teng Z; Zhang Y; Jin Y; Guo H; Yang Y; Wen X; Sun S
    Microb Pathog; 2020 Jun; 143():104130. PubMed ID: 32165331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preserved immunogenicity of an inactivated vaccine based on foot-and-mouth disease virus particles with improved stability.
    Caridi F; Vázquez-Calvo Á; Borrego B; McCullough K; Summerfield A; Sobrino F; Martín-Acebes MA
    Vet Microbiol; 2017 May; 203():275-279. PubMed ID: 28619156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.